VRTX Keeps Going Vertical

Vertex Pharmaceuticals cleared a 195.91 buy point from a nine-month consolidation, continuing to run up after the FDA OK'd its high-priced cystic fibrosis triple-drug regimen last week. But Vertex reports earnings late Wed. May want to consider options strategy or just play the earnings gap.